Effect of Physiological Concentrations of Vasopressin on Components of the Fibrinolytic System

Summary

High physiological concentrations of plasma vasopressin (aVP) when achieved by infusion cause an increase in plasma factor VIII coagulant activity and shortening of the euglobulin clot lysis time (ECLT). To investigate the effects of aVP on components of the fibrinolytic pathway and on thrombin generation, t healthy volunteers were infused with saline for 30 min followed by aVP for L hour and blood samples taken every 30 min for measurement of aVR ECtf tissue-type plasminogen activator (t-PA), t-PA inhibition (tPA-I), plasminogen activator inhibitor L (PAI-1 Ag), activated partial thromboplastin time (APTT), fibrinopeptide A (FPA), fibrinopeptide B 15-42 (FPBß 15-42) and crosslinked fibrin breakdown products (XL-FDP). Plasma aVP rose to a median of 75 pg/ml after 90 min and fell to 13.8 pdml 30 min later. The APTT fell from 43.5 to 35 sec (p <0.01) but there was no change in plasma FPA or in XL-FDP. Plasminogen activator activity (10⁶/ECLT²) increased from 25 to 736 units (p <0.01) and t-PA from 200 to 1012 mlU/ml (p <0.01). tPA-I fell from 8.0 to 2.7 IU/ml at 90 min (p <0.05) but PAI-1 Ag remained unchanged. Plasma FPBß 15-42 was 2.4 and 1.2 pmol/ml before infusion with aVP and showed a small rise to 3.5 pmol/ml after 60 min (p <0.05). The results show the effects of aVP on fibrinolysis are mediated by an increase in t-PA. In the absence of thrombin generation the rise in t-PA was not accompanied by changes in XL-FDP.

Keywords

Vasopressin - Tissue plasminogen activator - Fibrinolysis - Fibrinopeptide A

• References

• 1 Grant PJ, Stickland MH, Wiles PG, Davies JA, Wales JK, Prentice CR M. Hormonal control of haemostasis during hypoglycaemia in diabetes mellitus. Thromb Haemostas 1987; 57: 341-344
• 2 Grant PJ, Tate GM, Davies JA, William NS, Prentice CR M. Intraoperative activation of coagulation - a stimulus to thrombosis mediated by vasopressin. Thromb Haemostas 1986; 55: 104-107
• 3 Grant PJ, Hughes JR, Dean HG, Davies JA, Prentice CR M. Vasopressin and catecholamine secretion during apomorphine induced nausea mediate acute changes in haemostatic function in man. Clin Sci 1986; 71: 621-624
• 4 Biggs R, MacFarlane RG, Pilling J. Observations on fibrinolysis:experimental activity produced by exercise or adrenaline. Lancet 1947; 1: 402-405
• 5 Grant PJ, Davies JA, Tate GM, Boothby M, Prentice CR. Effects of physiological concentrations of vasopressin on haemostatic function in man. Clin Sci 1985; 69: 471-476
• 6 Thomas TH, Lee MR. The specificity of antisera for the radioimmunoassay of arginine vasopressin in human plasma and urine during water loading. Clin Sci Mol Med 1976; 51: 525-536
• 7 Thomson JM, Poller L. The activated partial thromboplastin time. In: Blood Coagulation and Haemostasis; A Practicle Guide. Thomson JM. (ed). Churchill Livingstone; Edinburgh: 1985. pp 301-339
• 8 Woodhams BJ, Kernhoff PB A. Rapid radioimmunoassay for fibrinopeptide A in human plasma. Thromb Res 1981; 22: 407-416
• 9 Kudryk B, Robinson D, Netre C, Hessel B, Blomback M, Blomback B. Measurement in human blood offibrinogen/fibrin fragments containing the Bß 15-42 sequence. Thromb Res 1982; 25: 277-291
• 10 Nilsson IM, Hedner U, Pandolfi M. The measurement of fibrinolytic activity. In: Fibrinolytes and Antifibrinolytes. Markwardt F. (ed) Springer-Verlag; Berlin: 1978. pp 107-134
• 11 Verheijen JH, Mullaart E, Chang GT G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
• 12 Verheijen JH, Chang GT G, Mullaart E. Inhibition of extrinsic (tissue-type) plasminogen activator by human plasma: evidence for the occurrence of a fast acting inhibitor. Thromb Haemostas 1982; 50: 294 (Abstr)
• 13 MacGregor IR, Booth NA. An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI-1). Thromb Haemostas 1988; 59: 68-72
• 14 Gaffney PJ, Creighton LJ, Perry MJ, Callus M, Thorpe R, Spitz M. Monoclonal antibodies to cross-linked fibrin degradation products (XL-FDP) I: Characterisation and preliminary evaluation in plasma. Br J Haematol 1988; 68: 83-90
• 15 Mannucci PM, Rota L. Plasminogen activator response after DDAVP: a clinico-pharmacological study. Thromb Res 1980; 20: 69-76
• 16 Menon C, Berry EW, Ockelford P. Beneficial effect of DDAVP on bleeding time in von Willebrand’s disease. Lancet 1978; 2: 743
• 17 Over H, Sixma JJ, Doucet de Bruine MH. et al Survival of 125-iodine-labelled factor VIII in normal and patients with classic haemophilia. Observations on the heterogeneity of human factor VIII J Clin Invest 1978; 62: 223-234
• 18 Wion KL, Kelly D, Summerfield JA, Tuddenham EG D, Lawn RM. Distribution of factor VIII RNA and antigen in human liver and other tissues. Nature 1985; 317: 726-728